BREAST CANCER: DRUGS FUNDING & TRIALS

Achieving world-class patient outcomes *(6 CPD points)*

A Pink Ribbon event **Thursday 23 March 2017, 9-5. Faculty of Pharmaceutical Medicine, London EC1V**

Booking link: http://tinyurl.com/jz9oev4

PROGRAMME

9 **Registration & coffee + exhibition**

9.30 **Welcome and introduction – Gerard Dugdill, publisher/coordinator Pink Ribbon**

Chair: Dr Kathleen Thompson, pharmaceutical physician, breast cancer patient & author, *From Both Ends of the Stethoscope*

MORNING SESSIONS

SECTION ONE – THE PROBLEMS

1. **PATIENT PERSPECTIVES**

How effective is the current breast cancer drugs regime?

9.40-10.15 Major issues: limits in availability of new effective treatments for metastatic breast cancer, poor access to clinical trials, inadequate use of data to facilitate research into cure, tissue banking.

Introductions (and introduction to white paper). Group discussion: Chair + patient advocates (Jo Taylor, MetupUK; Alison Dagul, breast and ovarian patient; Julia Bradford, Metup)

2. **SYSTEM PERSPECTIVES**

What are the key challenges in drug approval and funding?

Increasing breast cancer drug costs due to regulation, prevalence, survival rates, long drug approval time. NICE. UK lagging behind other countries. Funding restraints hindering prescription. Cancer Drugs Fund

10.15-10.30 ***Medical perspective: cancer funding and research needs***
Dr Aleksandra Filipovic, research fellow, department of surgery and cancer, Imperial College London

10.30-10.45 ***Pharma perspective: regulator approval and drug funding***
Dr David Montgomery, medical director, Pfizer Oncology UK

10.45-11 ***Buyer perspective: providing adequate cancer service and drugs***
Ms Raj Nijjar, Lead Cancer Pharmacist, Barts Health NHS Trust & Specialised Cancer Commissioning Pharmacist, NHS England – London Region

11-11.15 ***Life science + patient perspective: accelerated access review opportunities***
Dr Stuart Dollow, Head, Global Clinical Development and Medical Affairs at UCB; Founder - Vermilion Life Sciences; also, external champion to the Accelerated Access Review

11.15-11.30 ***PANEL: are we clear now on the key challenges for the industry?***
Problems section speakers

11.30-11.45 **Refreshments break**

SECTION TWO - THE SOLUTIONS

1. DRUG DEVELOPMENT

New ways to make and deliver drugs quickly and effectively

11.45-12 ***Oncologist focus: new drug possibilities, personalized medicine, genomics***
Dr Bhawna Sirohi, Consultant Medical Oncologist, Program Training Director – Medical Oncology, Barts Cancer Institute, London

12-12.30 ***New ways of doing drug development***
Speaker one: New ways of funding research. Lesley Turner, patient advocate, Catalyst Initiative
Speaker two: Professor Jackie Hunter, CEO, BenevolentBio (drug discovery arm of BenevolentAI)

12.30-12.45 ***Cancer patient data: linking the possibilities***
Dr Rachael Brock, national head of cancer registration, National Cancer Registration & Analysis Service, Public Health England (PHE)

12.45-1 ***Clinical trial database creation: getting it perfect***
Sarah Kimber, patient information manager, Cancer Research UK

1-1.15 ***PANEL: what one thing can we do to enhance innovative research?***
Drug development section speakers

1.15-2.15 **Lunch & exhibition**

AFTERNOON SESSIONS …SOLUTIONS CONTINUED

2. REGULATION

New approaches for approval, cost and reimbursement

2.15-2.35 ***Regulatory approval of breast cancer drugs***
Dr Cecilia Chisholm, medical assessor in licensing division, medicines and healthcare products regulatory agency (MHRA)

2.35-2.50 ***Regulation from an EU perspective***
Dr Francesco Pignatti, head of oncology, haematology and diagnostics, European Medicines Agency (EMA)

2.50-3.05 ***PANEL: how can we get the best possible regulation?***
Panel: regulation section speakers + extra, NHS England, NHS

3.05-3.20 **Tea break**

3. FUNDING

Collaboration: getting new drugs to patients

KEYNOTE

3.20-3.50 ***TOWARDS PARTNERSHIP APPROACHES IN FUNDING***
Open discussion

3.50-4.05 ***The new Cancer Drugs Fund***
Linda Landells, associate director – Technology Appraisals (Cancer Drugs Fund), national institute for clinical excellence (NICE)

4.05-4.25 ***Making drugs available earlier: how can we achieve?***
Professor Peter Clark, clinical lead, CDF, NHS England

4-25-4.45 ***PANEL: what must we do to fund all patient needs?***
Panel: funding section speakers

4.45-5 **Chair's closing remarks + call to action via white paper**

5 **Close**

Organised by

In aid of the national hereditary breast cancer helpline

Supported by Pfizer Limited